{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-04T21:41:43.268221+00:00","company":{"ticker":"IBRX","cik":1326110,"company_name":"ImmunityBio, Inc."},"pagination":{"limit":100,"returned":6,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"f3caa065651a7927426015e549f5f4ed7b3b5ca2","cik":1326110,"ticker":"IBRX","company_name":"ImmunityBio, Inc.","filed_at":"2026-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the three months ended March 31, 2026","report_date":"2026-05-07","result_type":"reported_results","revenue_text":"$44.2 million"},"claim":"ImmunityBio, Inc. reported the three months ended March 31, 2026 results: revenue $44.2 million.","evidence_excerpt":"9 – Financial Statements and Exhibits. \n\n--- EX-99.1 (EX-99.1) ---\n\nImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million • Q1 2026 Revenue Growth with Continued Strong","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001326110-26-000057","anchor_url":"https://secwatch.observer/filing/0001326110-26-000057#claim-f3caa065651a7927426015e549f5f4ed7b3b5ca2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000057/0001326110-26-000057-index.htm"},{"fact_type":"earnings_release","fact_key":"373fd401c9005473866c9e6eeaa21b761cba6610","cik":1326110,"ticker":"IBRX","company_name":"ImmunityBio, Inc.","filed_at":"2026-04-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fiscal quarter ending March 31, 2026","report_date":"2026-03-31","result_type":"preliminary_results","revenue_text":"approximately $44.2 million"},"claim":"ImmunityBio, Inc. reported the fiscal quarter ending March 31, 2026 results: revenue approximately $44.2 million.","evidence_excerpt":"ImmunityBio reported preliminary net product revenue of approximately $44.2 million during the three-month period ending March 31, 2026","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001326110-26-000036","anchor_url":"https://secwatch.observer/filing/0001326110-26-000036#claim-373fd401c9005473866c9e6eeaa21b761cba6610","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000036/0001326110-26-000036-index.htm"},{"fact_type":"debt_financing","fact_key":"6d0e45b4f29132fcf4dcbd0413d59cf1995535b6","cik":1326110,"ticker":"IBRX","company_name":"ImmunityBio, Inc.","filed_at":"2026-03-31T23:59:59+00:00","payload":{"counterparty":"Infinity SA LLC, as collateral agent and administrative agent for the Purchasers","effective_date":"2026-03-30","event":"incurrence","instrument_type":"other","interest_rate_text":"tiered range of 5.625% to 12.50%","item_codes_triggered":["2.03"],"maturity_text":null,"principal_text":"$75.0 million"},"claim":"ImmunityBio, Inc. incurred debt of $75.0 million with Infinity SA LLC, as collateral agent and administrative agent for the Purchasers at tiered range of 5.625% to 12.50%.","evidence_excerpt":"(the “Company”) entered into a Second Amendment to Revenue Interest Purchase Agreement (the “Amendment”) by and among the Company, the guarantors party thereto, the purchasers party thereto (the “Purchasers”) and Infinity SA LLC, as collateral agent and administrative agent for the Purchasers (the “Agent”), which amends that certain Revenue Interest Purchase Agreement dated as of December 29, 2023, by and among the Company, the Purchasers and the Agent (as amended, modified and supplemented prior to the date of the Amendment, the “RIPA”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-133363","anchor_url":"https://secwatch.observer/filing/0001193125-26-133363#claim-6d0e45b4f29132fcf4dcbd0413d59cf1995535b6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326110/000119312526133363/0001193125-26-133363-index.htm"},{"fact_type":"material_agreement","fact_key":"5c56a3dc7d522cfafc9364c614119b38238cfa13","cik":1326110,"ticker":"IBRX","company_name":"ImmunityBio, Inc.","filed_at":"2026-01-26T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Convertible Note Amendment","agreement_type":"notes_offering","counterparty":"Nant Capital, LLC","effective_date":"2026-01-23","item_codes_triggered":["1.01"],"value_text":null},"claim":"ImmunityBio, Inc. amended Convertible Note Amendment with Nant Capital, LLC (effective 2026-01-23).","evidence_excerpt":"On January 23, 2026, ImmunityBio, Inc. (the “Company”) entered into a letter amendment (the “Convertible Note Amendment”) to that certain convertible Second Amended and Restated Promissory Note, dated December 10, 2024, in an outstanding principal amount of $505.0 million (the “Convertible Promissory Note”), by and among the Company and Nant Capital, LLC (the “Holder”), an entity affiliated with Dr. Patrick Soon-Shiong, the Company’s Executive Chairman and Global Chief Scientific and Medical Officer.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001326110-26-000014","anchor_url":"https://secwatch.observer/filing/0001326110-26-000014#claim-5c56a3dc7d522cfafc9364c614119b38238cfa13","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000014/0001326110-26-000014-index.htm"},{"fact_type":"material_agreement","fact_key":"7f4e18a90d431a4bc8734ecaac37f6bce8923668","cik":1326110,"ticker":"IBRX","company_name":"ImmunityBio, Inc.","filed_at":"2025-12-29T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amendment No. 1","agreement_type":"atm_program","counterparty":"Jefferies LLC","effective_date":"2025-12-23","item_codes_triggered":["1.01"],"value_text":"$459,972,480"},"claim":"ImmunityBio, Inc. amended Amendment No. 1 with Jefferies LLC valued at $459,972,480 (effective 2025-12-23).","evidence_excerpt":"On December 23, 2025, ImmunityBio, Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment to Sale Agreement”) to the Open Market Sale Agreement SM dated April 30, 2021, (the “Sale Agreement”) with Jefferies LLC (the “Agent”) relating to the sale and issuance of shares of its common stock, par value $0.0001 per share (the “Shares”), from time to time through an “at the market” offering program under which the Agent acts as the Company’s sales agent.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-331244","anchor_url":"https://secwatch.observer/filing/0001193125-25-331244#claim-7f4e18a90d431a4bc8734ecaac37f6bce8923668","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326110/000119312525331244/0001193125-25-331244-index.htm"},{"fact_type":"executive_change","fact_key":"e89e77fecf","cik":1326110,"ticker":"IBRX","company_name":"ImmunityBio, Inc.","filed_at":"2025-02-07T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-07","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"John Owen Brennan resigned as Director at ImmunityBio, Inc..","evidence_excerpt":"On February 7, 2025, John Owen Brennan notified the Secretary of ImmunityBio, Inc., a Delaware corporation (the “Company”) of his resignation as a member of the Company’s Board of Directors (the “Board”) and from all committees of the Board on which he served, effective as of February 7, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-022776","anchor_url":"https://secwatch.observer/filing/0001193125-25-022776#claim-e89e77fecf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326110/000119312525022776/0001193125-25-022776-index.htm"}]}